CA-RIX-INDUSTRIES
RIX Industries (“RIX”), a leading developer of pneumatic energy technology, announced today that it has licensed proprietary methanol-based M-Series hydrogen generator technology from Element 1 Corp (e1). Under the terms of the license agreement, RIX has been granted rights to manufacture and deploy e1’s M-Series on-board hydrogen generators for use in fuel cell mobility applications, including marine vessels and off-road vehicles such as mining trucks, tractors, and heavy-lift trucks in both North America and Europe.
Governments across the globe are striving to reduce harmful emissions into the air and waterways. Tightening regulations combined with corporate sustainability initiatives are driving a massive migration to non-polluting electric propulsion systems, many of which utilize hydrogen fuel cells. RIX’s history of supporting the maritime industry, including the US Navy, together with e1’s methanol to hydrogen generator offers end-users an opportunity to adopt fuel cell motive solutions and work towards a zero-emissions future.
“RIX Industries has a global reputation for excellence and the addition of e1’s class-leading technology to our portfolio strategically aligns with our brand and our growth strategy,” said Bryan Reid, Chief Sales Officer at RIX. “We are focused on the clean energy future and firmly believe that there is a significant market opportunity that can be effectively addressed by RIX incorporating e1’s M-Series hydrogen generator into power solutions.”
Dr. David Edlund, e1 CEO, said, “e1 is delighted and privileged to be collaborating with RIX. They are a first-class manufacturing partner and a long-time authorized supplier to multiple branches of the U.S. military along with a wide range of commercial and industrial end-users. The on-board hydrogen generation technology being licensed to RIX is unique to e1 and is highly enabling to the mass commercialization of fuel cell systems for a wide variety of transportation-related fuel cell applications. I anticipate our relationship with RIX to broaden substantially over the not too distant future,” concluded Dr. Edlund.
The onboard storage of methanol used by e1’s hydrogen generators requires a fraction of the space on a maritime vessel as compared to compressed hydrogen, enabling a significantly greater range between fueling. This range extension is critical for not only marine vessels but also for heavy and medium-duty fuel cell trucks traveling long distances each day.
About RIX Industries:
Founded in 1878, RIX Industries is a technology-focused company, headquartered in Benicia, CA, specializing in the design, development and manufacture of pneumatic energy storage, transfer and control system solutions, including gas generation systems, precision compressor solutions and cryogenic cooling technologies for critical applications in Marine, Aerospace, Land, Energy, Industrial and Medical markets.
Visit www.CreateCompressCool.com for more information.
About Element 1 Corporation:
Element 1 designs and develops novel processes to enable the commercialization of clean-energy products and processes and alternative-energy technology. Through licensing our IP to strategic partners, our mission is to significantly reduce barriers to the adoption of hydrogen technology and fuel cells for a range of applications and to reduce the waste and pollution associated with flaring natural gas.
For more information about Element 1, please visit www.e1na.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005856/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
